<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335246">
  <stage>Registered</stage>
  <submitdate>12/03/2010</submitdate>
  <approvaldate>22/03/2010</approvaldate>
  <actrnumber>ACTRN12610000235000</actrnumber>
  <trial_identification>
    <studytitle>Impact of topical lignocaine on the incidence of perioperative respiratory complications in children undergoing laryngo-tracheo-bronchoscopies  a double blind randomised controlled pilot study</studytitle>
    <scientifictitle>Impact of topical lignocaine on the incidence of perioperative respiratory complications in children undergoing laryngo-tracheo-bronchoscopies  a double blind randomised controlled pilot study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Respiratory complications following topical lignocaine onto the vocal cords for laryngotracheobronchoscopies</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Topical lignocaine vs. placebo onto vocal cords for a laryngo-tracheo-bronchoscopy.
The lignocaine is applied directly following induction of anaesthesia. It is only applied once which takes one spray of lignocaine of 5-10 seconds duration.
The lignocaine dose used will be a maximum of 4 mg/kg as topical spray (under vision) onto the vocal cords. For this trial, lignocaine 4% will be used in all children. In children &gt; 30 kg 3 ml of lignocaine 4% will be applied.</interventions>
    <comparator>Saline.
The saline is sprayed as a once off spray (identical to lignocaine) directly following induction of anaesthesia. The application of the spray takes approx. 5-10 seconds.
The control group will receive the equivalent amount of normal saline in ml as compared to the lignocaine dose</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>the total of respiratory complications intraoperatively and postoperatively.
Assessment by clinical examination and monitoring</outcome>
      <timepoint>intraoperatively plus during the stay in the recovery room area</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>the occurrence of the individual respiratory complication.
Assessment by clinical examination and monitoring</outcome>
      <timepoint>intraoperatively plus during the stay in the recovery room area</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children, aged 0 to 16 years, male or female undergoing an laryngo-tracheo-bronchoscopy (LTB).</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Hypersensitivity to lignocaine, airway reconstruction surgery</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Written voluntary consent consisting of parental permission and also child assent when applicable, will be obtained and great care will be taken to maintain the highest standards regarding consent for clinical research in paediatric anaesthesia. The children will be included into the trial at the preanaesthetic visit. Following inclusion into the study protocol, the children will be randomly assigned to group “lignocaine” or group “saline” by computer generated block randomisation. The anaesthetist in charge, the ENT surgeon and the recovery staff will be blinded to the substance used to spray on the cords (lignocaine vs saline). Allocation was concealed in sealed opaque envelopes
</concealment>
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2010</anticipatedstartdate>
    <actualstartdate>18/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>20/09/2013</actualenddate>
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Princess Margaret Hospital - Subiaco</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof Britta Regli-von Ungern-Sternberg</primarysponsorname>
    <primarysponsoraddress>Princess Margaret Hospital for Children
Department of Anaesthesia
Roberts Road 
Subiaco, WA 6008</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Princess Margaret Hospital for Children</fundingname>
      <fundingaddress>Department of Anaesthesia
Roberts Road 
Subiaco, WA 6008</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Tim Cooney</sponsorname>
      <sponsoraddress>Princess Margaret Hospital for Children
Department of Ear-Nose and Throat Surgery
Roberts Road 
Subiaco, WA 6008</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>the purpose of this study is to characterize the modification induced by lignocaine on the incidence of intraoperative and postoperative respiratory complications in children undergoing laryngo tracheo bronchoscopies.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Princess Margaret Hospital for Children Ethics Committee</ethicname>
      <ethicaddress>Roberts Road
Subiaco
WA 6008</ethicaddress>
      <ethicapprovaldate>20/08/2009</ethicapprovaldate>
      <hrec>1640 EP</hrec>
      <ethicsubmitdate>1/07/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Britta Regli-von Ungern</name>
      <address>Department of Anaesthesia
Roberts Road 
Subiaco, WA 6008</address>
      <phone>+61893408109</phone>
      <fax />
      <email>britta.regli-vonungern@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Britta Regli-von Ungern-Sternberg  </name>
      <address>Department of Anaesthesia
Roberts Road 
Subiaco, WA 6008</address>
      <phone>+61893408109</phone>
      <fax>+61893408755</fax>
      <email>britta.regli-vonungern@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Britta Regli-von Ungern-Sternberg  </name>
      <address>Department of Anaesthesia and Pain Management
Princess Margaret Hospital
Roberts Road,
Subiaco
WA 6008</address>
      <phone>+61893408109</phone>
      <fax />
      <email>britta.regli-vonungern@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Britta Regli-von Ungern-Sternberg  </name>
      <address>Department of Anaesthesia and Pain Management
Princess Margaret Hospital
Roberts Road,
Subiaco
WA 6008</address>
      <phone>+61893408109</phone>
      <fax />
      <email>britta.regli-vonungern@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>